Nephrocare Health Services Limited (NEPHROPLUS) fundamentals
Nephrocare Health Services Limited is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as NEPHROPLUS (ISIN INE428V01029). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Nephrocare Health Services Limited does
Nephrocare Health Services Limited, formerly Nephrocare Health Services Pvt Ltd, is an India-based company. The Company is primarily engaged in the business of providing dialysis and sale of related healthcare services and products. The Company offers comprehensive dialysis care through the network of clinics from diagnosis to treatment and wellness programs including hemodialysis, home and mobile dialysis, supported by a pharmacy. It has a network of approximately 490 clinics, with 43 clinics internationally across the Philippines, Uzbekistan and Nepal. Its subsidiaries include Nephrocare Health Services Central Asia FE LLC, Nephrocare Health Services International Pte. Ltd, Nephrocare Health Services Nepal Private Limited, and others.
Valuation and market data
| Last close | ₹765.35 |
|---|---|
| Market capitalisation | ₹6,935 crore |
| Enterprise value | ₹6,866 crore |
| P/E (TTM) | 90.25 |
| Price to book | 6.21 |
| Price to sales (TTM) | 3.85 |
| Book value per share | ₹123.22 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Wed Dec 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹645 crore | ₹-4 crore | ₹-8 crore | -0.89 |
| Mar 2025 | ₹559 crore | ₹45 crore | ₹34 crore | 4.23 |
| Mar 2024 | ₹444 crore | ₹0 crore | ₹4 crore | 0.50 |
| Mar 2023 | ₹391 crore | ₹-13 crore | ₹-15 crore | -29.86 |
| Mar 2022 | ₹320 crore | ₹-28 crore | ₹-22 crore | -132.53 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 63.9% |
|---|---|
| Foreign institutions (FII) | 8.8% |
| Mutual funds | 3.2% |
| Other domestic institutions | 5.8% |
| Retail and others | 18.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.